HCW Biologics regains Nasdaq compliance; subject to one-year monitoring period

HCW Biologics Inc.

Nasdaq Hearings Panel found Company regained compliance with all continued listing rules on Feb 26, 2026.
Company demonstrated compliance with Equity Rule by Dec 31, 2025 and other rules by Feb 16, 2026.
Company subject to Mandatory Panel Monitor for one year; immediate delisting if Equity Rule violated again.
If non-compliant during monitor, Staff will issue Delist Determination Letter; Company can request new hearing.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.